The U.S. Department of Health and Human Services has announced they will begin analyzing trends in the use of add-on testing, such as respiratory pathogen panel (RPP), allergy, and genetic testing, in order to locate patterns in billing that may indicate fraud. While relaxed rules put in place by the CARES Act and Families First Coronavirus Response Act (FFCRA) allowing providers to conduct diagnostic COVID testing without an order from a treating physician are helpful to in-need communities, the Office of Inspector General states that these rules may open the door for improper billing related to add-on testing.